Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
We are pleased to introduce two new HSO reports.
Health Technology Assessment HTA has in many countries become an integral part of health policy decision-making. After the assessment (the synthesis of available research evidence) some countries undertake an appraisal of the evidence’s impact and applicability for a specific context. Appraisal committees, sometimes called policy committees, work where research and policy meet. Appraisal committees facilitate the life of decision makers in health policy by translating research results into political recommendations. This working paper presents 11 appraisal committees from 7 countries and condenses their experience into recommendations. An appraisal committee set up in line with these examples of good-practice may serve as an important building block for transparent and evidence-based decision making in health policy.
Publication: Decision Support Document Nr. 72: http://eprints.hta.lbg.ac.at/1036
Contact: Claudia Wild
Costs of day surgery in Austria: An analysis of data and methods for varicose vein surgery as an example
The report contains an analysis of data and methods to calculate the costs of day surgery and inpatient treatment in Austria. Thus, varicose vein surgery was chosen as an example to proof several data sources for their applicability. Beside the calculation by using Austrian meta data and international costs from the UK, we used costs from individual hospitals. The calculated costs differed between 859 and 4,664 Euros for day surgery and 1,720-2,330 Euros for an inpatient treatment.
Publication: LBI-HTA Project report No. 71: http://eprints.hta.lbg.ac.at/1035
Contact: Stefan Fischer
We are pleased to introduce our new HSO report.
Using cost-effectivenes analysis to influence health policy: the example of radon control
September 16th 2014/4-5 pm
Jugendstilhoersaal, MUV, BT 88, Level 2
Spitalgasse 23, 1090 Vienna, Austria
Within the project Horizon Scanning in Oncology 9 databases are frequently scanned to identify new/emerging oncologic drugs. Every 3 months, these drugs are filtered according to predefined criteria (i.e. in most instances availability of phase III study results) and are then prioritised by an expert panel to identify those therapies for which either a substantial clinical or financial impact can be expected.
We are pleased to introduce our new reports.
Decision Support Documents 2014:
DSD 74: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis
DSD 75: Drug eluting stents for the treatment of peripheral artery disease
DSD 76: Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases
DSD 20/ Update 2014: Implantation of endobronchial valves in patients with emphysema
DSD 44/1. Update 2014: Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (1st Update 2014)